NEW YORK (GenomeWeb) – Thermo Fisher Scientific has launched a program by which it will collaborate with partners to develop its next-generation sequencing-based Oncomine portfolio of products into clinical tests that can be used as companion diagnostics. The Institute of Medical Genetics and Pathology at University Hospital Basel, Switzerland will be the first partner in the initiative, dubbed the Next Generation Companion Dx Center of Excellence Program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
20

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.